89 related articles for article (PubMed ID: 7273016)
1. Phase I trial of PCNU administered by 5-day courses.
Earhart RH; Koeller JM; Davis HL
Cancer Treat Rep; 1981; 65(9-10):835-40. PubMed ID: 7273016
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of PCNU.
Kalman LA; Gralla RJ; Casper ES; Kris MG; Gordon C; Woodcock TM
Cancer Treat Rep; 1983 Nov; 67(11):1027-9. PubMed ID: 6315229
[TBL] [Abstract][Full Text] [Related]
3. Activity of JM9 in advanced ovarian cancer: a phase I-II trial.
Bramwell VH; Crowther D; O'Malley S; Swindell R; Johnson R; Cooper EH; Thatcher N; Howell A
Cancer Treat Rep; 1985 Apr; 69(4):409-16. PubMed ID: 3995511
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of ICRF-187 by 48-hour continuous infusion.
Koeller JM; Earhart RH; Davis HL
Cancer Treat Rep; 1981; 65(5-6):459-63. PubMed ID: 6786740
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of 6-diazo-5-oxo-L-norleucine (DON) administered by 5-day courses.
Earhart RH; Koeller JM; Davis HL
Cancer Treat Rep; 1982 May; 66(5):1215-7. PubMed ID: 7083223
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion.
Egorin MJ; Sigman LM; Van Echo DA; Forrest A; Whitacre MY; Aisner J
Cancer Res; 1987 Jan; 47(2):617-23. PubMed ID: 3791246
[TBL] [Abstract][Full Text] [Related]
7. Phase I evaluation of semustine in a weekly schedule.
Koller CA; Schwalm D; Liepman M; Natale RB; Wheeler RH
Cancer Treat Rep; 1983 Jun; 67(6):579-81. PubMed ID: 6861164
[TBL] [Abstract][Full Text] [Related]
8. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
9. [Phase I study of 1-(2-chloroethyl)-3-isobutyl-3-(beta-maltosyl)-1-nitrosourea (TA-077). Phase I Study Group].
Gan To Kagaku Ryoho; 1986 Jul; 13(7):2425-33. PubMed ID: 3729497
[TBL] [Abstract][Full Text] [Related]
10. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical study of the new amino acid-linked nitrosourea, S 10036, administered on a weekly schedule.
Khayat D; Lokiec F; Bizzari JP; Weil M; Meeus L; Sellami M; Rouesse J; Banzet P; Jacquillat C
Cancer Res; 1987 Dec; 47(24 Pt 1):6782-5. PubMed ID: 3677107
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of recombinant interleukin 3 before and after carboplatin/etoposide chemotherapy in patients with solid tumors: a southwest oncology group study.
Rinehart J; Margolin KA; Triozzi P; Hersh E; Campion M; Resta D; Levitt D
Clin Cancer Res; 1995 Oct; 1(10):1139-44. PubMed ID: 9815905
[TBL] [Abstract][Full Text] [Related]
13. Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390).
Arteaga CL; Brown TD; Kuhn JG; Shen HS; O'Rourke TJ; Beougher K; Brentzel HJ; Von Hoff DD; Weiss GR
Cancer Res; 1989 Aug; 49(16):4648-53. PubMed ID: 2743343
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitrosourea (NSC 95466) in adults with solid tumors.
Stewart DJ; Benjamin RS; Leavens M; Valdivieso M; Burgess MA; Bodey GP
Cancer Res; 1980 Oct; 40(10):3750-4. PubMed ID: 6254639
[No Abstract] [Full Text] [Related]
15. [Phase I trial of 4'-O-tetrahydropyranyl-doxorubicin (THP)--a multi-institutional cooperative study].
Wakui A; Yokoyama M; Konno K; Nakai Y; Sakano T; Koyama Y; Imamura Y; Nakajima O; Niijima T; Akaza H
Gan To Kagaku Ryoho; 1985 Jan; 12(1):118-24. PubMed ID: 3966806
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial and clinical pharmacology of 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitrosourea.
Woolley PV; Luc PV; Rahman A; Korsmeyer SJ; Smith FP; Schein PS
Cancer Res; 1981 Oct; 41(10):3896-900. PubMed ID: 7284999
[TBL] [Abstract][Full Text] [Related]
17. [Phase I study on oral administration of methyl-6-[[[(2-chloroethyl) nitrosoamino] carbonyl] amino]-6-deoxy-alpha-D-glucopyranoside (MCNU)].
Kanamaru A; Nagai K; Fujita S; Masaoka T; Takubo T; Kitani T; Taniguchi N; Horiuchi A; Tsubaki K; Kawagoe H; Hirata M; Yonezawa T; Tsubakio T; Yasunaga K; Okamoto Y; Fujitake H; Ohkubo A
Gan To Kagaku Ryoho; 1983 Aug; 10(8):1831-7. PubMed ID: 6882006
[TBL] [Abstract][Full Text] [Related]
18. Phase I clinical and pharmacologic trial of carboplatin daily for 5 days.
Van Echo DA; Egorin MJ; Whitacre MY; Olman EA; Aisner J
Cancer Treat Rep; 1984 Sep; 68(9):1103-14. PubMed ID: 6383605
[TBL] [Abstract][Full Text] [Related]
19. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.
Supko JG; Balcerzak SP; Kraut EH
Cancer Res; 1993 Oct; 53(20):4843-9. PubMed ID: 8402671
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of triglycidylurazol given on a 5-day i.v. schedule.
Nicaise C; Rozencweig M; Crespeigne N; Dodion P; Gerard B; Lambert M; Decoster G; Kenis Y
Cancer Treat Rep; 1986 May; 70(5):599-603. PubMed ID: 3708609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
